Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neurofibromatoses Type II - Overview
Neurofibromatoses Type II - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Neurofibromatoses Type II - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neurofibromatoses Type II - Companies Involved in Therapeutics Development
AstraZeneca Plc
Beta Pharma Inc
BioXcel Corp
Millennium Pharmaceuticals Inc
Mulberry Biotherapeutics Inc
OncoTherapy Science Inc
Plex Pharmaceuticals Inc
PRG S&Tech Inc
Recursion Pharmaceuticals Inc
Neurofibromatoses Type II - Drug Profiles
bortezomib - Drug Profile
Product Description
Mechanism Of Action
History of Events
brigatinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
icotinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
MUL-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PRG-NF - Drug Profile
Product Description
Mechanism Of Action
REC-2282 - Drug Profile
Product Description
Mechanism Of Action
History of Events
selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for Neurofibromatosis Type 2 - Drug Profile
Product Description
Mechanism Of Action
Vaccine to Target VEGFR1 and VEGFR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
Neurofibromatoses Type II - Dormant Projects
Neurofibromatoses Type II - Product Development Milestones
Featured News & Press Releases
May 11, 2012: Arno Therapeutics Receives European Orphan Drug Desigtion For AR-42
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Neurofibromatoses Type II, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Neurofibromatoses Type II, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Neurofibromatoses Type II - Pipeline by AstraZeneca Plc, 2022
Neurofibromatoses Type II - Pipeline by Beta Pharma Inc, 2022
Neurofibromatoses Type II - Pipeline by BioXcel Corp, 2022
Neurofibromatoses Type II - Pipeline by Millennium Pharmaceuticals Inc, 2022
Neurofibromatoses Type II - Pipeline by Mulberry Biotherapeutics Inc, 2022
Neurofibromatoses Type II - Pipeline by OncoTherapy Science Inc, 2022
Neurofibromatoses Type II - Pipeline by Plex Pharmaceuticals Inc, 2022
Neurofibromatoses Type II - Pipeline by PRG S&Tech Inc, 2022
Neurofibromatoses Type II - Pipeline by Recursion Pharmaceuticals Inc, 2022
Neurofibromatoses Type II - Dormant Projects, 2022